Key statistics
As of last trade Esperion Therapeutics Inc (0IIM:LSE) traded at 2.12, -37.00% below its 52-week high of 3.37, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 2.12 |
Low | 2.12 |
Bid | -- |
Offer | -- |
Previous close | 2.12 |
Average volume | 19.80k |
---|---|
Shares outstanding | 196.22m |
Free float | 195.24m |
P/E (TTM) | -- |
Market cap | 406.19m USD |
EPS (TTM) | -0.8758 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 19:06 BST.
More ▼
Announcements
- Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
- Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
- Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
- Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
- Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion to Report Second Quarter 2024 Financial Results on August 12
- Esperion to Participate in Upcoming BTIG Biotech Conference
- New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
More ▼